Loading
A phase 2 trial of durvalumab and olaparib in gallbladder cancer and other biliary tract cancers, run by Asan Medical Center, now recruiting.
Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy is a phase 2, randomised interventional study registered as NCT05222971 by Asan Medical Center, with a registry enrolment figure of 62 participants, started 2022-04-01 and due to reach its primary completion in 2025-12-30. Interventions recorded: Durvalumab, Olaparib. Conditions listed: Biliary Tract Cancer, DNA Damage Repair Deficiency. Gallbladder cancer is named in the registry entry: "* Histologically confirmed adenocarcinoma of biliary tract (intrahepatic, extrahepatic cholangiocarcinoma, or gallbladder carcinoma).". Sites: South Korea. No results are recorded here; the registry entry is the source.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
Shares PARP inhibitors, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Olaparib, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab and the tag gallbladder-deep-dive.